We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ROIV market cap is 7.75B. The company's latest EPS is USD 6.0948 and P/E is 1.78.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 37.14M | 28.93M | 55.13M | -42.67M | 9.02M |
| Operating Income | -287.53M | -266M | -230.57M | -323.76M | -274.38M |
| Net Income | 5.1B | -151.12M | 95.3M | -230.18M | 169.38M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 67.69M | 23.8M | 55.29M | 61.28M | 124.8M |
| Operating Income | -553.81M | -1.07B | -1.35B | -1.18B | -1.11B |
| Net Income | 1.2B | -809.23M | -845.26M | -1.01B | 4.35B |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 7.31B | 7.22B | 6.5B | 6.21B | 5.79B |
| Total Liabilities | 728.1M | 773.95M | 601.16M | 625.99M | 256.38M |
| Total Equity | 6.58B | 6.45B | 5.9B | 5.58B | 5.54B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 2.48B | 2.59B | 2.59B | 2.39B | 7.22B |
| Total Liabilities | 368.36M | 527.69M | 523.7M | 782.02M | 773.95M |
| Total Equity | 2.09B | 2.04B | 2.04B | 1.61B | 6.45B |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -656.81M | -765.27M | -192.83M | -459.64M | -666.89M |
| Investing | 5.2B | 5.2B | -965k | -3.29B | -2.84B |
| Financing | 451.99M | 419.36M | -660.62M | -769.69M | -1.04B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -758.75M | -552.14M | -677.73M | -843.39M | -765.27M |
| Investing | 1.69B | -31.7M | 303.3M | -44.27M | 5.2B |
| Financing | 214.08M | 456.26M | 306.79M | 499.46M | 419.36M |
| Market Cap | 7.75B |
| Price to Earnings Ratio | 1.78 |
| Price to Sales Ratio | 62.09 |
| Price to Cash Ratio | 1.19 |
| Price to Book Ratio | 1.2 |
| Dividend Yield | - |
| Shares Outstanding | 713.55M |
| Average Volume (1 week) | 3.63M |
| Average Volume (1 Month) | 5.72M |
| 52 Week Change | -3.81% |
| 52 Week High | 13.055 |
| 52 Week Low | 8.73 |
| Spread (Intraday) | 0.24 (2.16%) |
| Company Name | Roivant Sciences Ltd |
| Address |
clarendon house hamilton D0 HM11 |
| Website | https://www.roivant.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
